Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.

PloS one - 1 Jan 2014

Yoon Heejei, Choi Yoon-La, Song Ji-Young, Do Ingu, Kang So Young, Ko Young-Hyeh, Song Sangyong, Kim Byoung-Gie

Abstract excerpt

Ovarian clear cell carcinoma (OCCC) displays a higher resistance to first line chemotherapy, requiring the development of new therapeutics. We previously identified a frequent chromosomal gain at 8q24 that harbors the focal-adhesion kinase (FAK) gene; the potential of this gene as a therapeutic t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Antineoplastic Agents
Share to bcl-X Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Kinase 1

Share to Focal Adhesion Kinase 2

Share to Gene Dosage

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24523919
DOI: 10.1371/journal.pone.0088587
PMCID: PMC3921183

Genes

MCL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24523919-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.PMID 24523919Read ↗

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.Semantic proximity Read ↗

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.Semantic proximity Read ↗

Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsSemantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in CancerSemantic proximity Read ↗

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423Semantic proximity Read ↗

FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeuticsSemantic proximity Read ↗

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinomaSemantic proximity Read ↗

p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma.Semantic proximity Read ↗

FAK signaling in human cancer as a target for therapeuticsSemantic proximity Read ↗

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.